Ovarian Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

  • Published : Jul-2017
  • Tables : 241
  • Figures : 81
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT51MR
  • Format : ppt

Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself.

The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone. In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years. Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively. This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.

Market Taxonomy

Cancer Type

End User

Test Type

Epithelial Tumors

Hospital Associated Labs

CA 125

Germ cell carcinoma tumors

Independent Diagnostic Laboratories

HER 2

Stromal carcinoma tumors

Cancer Research Institutes

BRCA

 

Others

CEA

   

ER & PR

   

KRAS Mutation

   

Others

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Epithelial Tumours Segment larger than the other two combined

The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumours segment is marginal at best when contrasted with epithelial tumours in the ovarian cancer diagnostics market. The stromal carcinoma tumours segment is likely to be valued at only US$ 28 million in 2017.

Hospital associated and independent diagnostic labs most vital

The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.

Focus on CA 125 test segment in the ovarian cancer diagnostics market

The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.

Competition Tracking

The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Chapter 1. Global Ovarian Cancer Diagnostics Market - Executive Summary. 26

Chapter 2. Global Ovarian Cancer Diagnostics Market Overview. 28
2.1. Introduction. 28
       2.1.1. Global Ovarian Cancer Diagnostics Market Taxonomy. 28
       2.1.2. Global Ovarian Cancer Diagnostics Market Definition. 28
2.2. Global Ovarian Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 28
       2.2.1. Global Ovarian Cancer Diagnostics Market Y-o-Y Growth. 28
2.3. Global Ovarian Cancer Diagnostics Market Dynamics. 29
       2.3.1. Drivers. 29
       2.3.2. Restraints. 29
       2.3.3. Trends. 29
2.4. Supply Chain. 30
2.5. Epidemiology. 30
2.6. List of Distributors. 30
2.7. Average Pricing Analysis. 30
2.8. Regulations. 30
2.9. Key Participants Market Presence (Intensity Map) By Region. 31

Chapter 3. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Cancer Type. 32
3.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Cancer Type, 2012-2022. 32
       3.1.1. Epithelial Tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.1.2. Market Share Comparison, By Region. 34
                3.1.1.3. Y-o-Y growth Comparison, By Region. 34
       3.1.2. Germ cell carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.2.2. Market Share Comparison, By Region. 37
                3.1.2.3. Y-o-Y growth Comparison, By Region. 37
       3.1.3. Stromal carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 38
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 38
                3.1.3.2. Market Share Comparison, By Region. 40
                3.1.3.3. Y-o-Y growth Comparison, By Region. 40

Chapter 4. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By End User. 42
4.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 42
       4.1.1. Hospital Associated Labs Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 42
                4.1.1.2. Market Share Comparison, By Region. 44
                4.1.1.3. Y-o-Y growth Comparison, By Region. 44
       4.1.2. Independent Diagnostic Laboratories Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 45
                4.1.2.2. Market Share Comparison, By Region. 47
                4.1.2.3. Y-o-Y growth Comparison, By Region. 47
       4.1.3. Cancer Research Institutes Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 48
                4.1.3.2. Market Share Comparison, By Region. 50
                4.1.3.3. Y-o-Y growth Comparison, By Region. 50
       4.1.4. Others Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 51
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 51
                4.1.4.2. Market Share Comparison, By Region. 53
                4.1.4.3. Y-o-Y growth Comparison, By Region. 53

Chapter 5. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Test Type. 55
5.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 55
       5.1.1. CA 125 Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
                5.1.1.1. Revenue (US$ Mn) Comparison, By Region. 55
                5.1.1.2. Market Share Comparison, By Region. 56
                5.1.1.3. Y-o-Y growth Comparison, By Region. 57
       5.1.2. HER 2 Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 58
                5.1.2.1. Revenue (US$ Mn) Comparison, By Region. 58
                5.1.2.2. Market Share Comparison, By Region. 59
                5.1.2.3. Y-o-Y growth Comparison, By Region. 60
       5.1.3. BRCA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 61
                5.1.3.1. Revenue (US$ Mn) Comparison, By Region. 61
                5.1.3.2. Market Share Comparison, By Region. 62
                5.1.3.3. Y-o-Y growth Comparison, By Region. 63
       5.1.4. CEA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                5.1.4.1. Revenue (US$ Mn) Comparison, By Region. 64
                5.1.4.2. Market Share Comparison, By Region. 65
                5.1.4.3. Y-o-Y growth Comparison, By Region. 66
       5.1.5. ER & PR Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 67
                5.1.5.1. Revenue (US$ Mn) Comparison, By Region. 67
                5.1.5.2. Market Share Comparison, By Region. 68
                5.1.5.3. Y-o-Y growth Comparison, By Region. 69
       5.1.6. KRAS Mutation Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 70
                5.1.6.1. Revenue (US$ Mn) Comparison, By Region. 70
                5.1.6.2. Market Share Comparison, By Region. 71
                5.1.6.3. Y-o-Y growth Comparison, By Region. 72
       5.1.7. Others Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 73
                5.1.7.1. Revenue (US$ Mn) Comparison, By Region. 73
                5.1.7.2. Market Share Comparison, By Region. 74
                5.1.7.3. Y-o-Y growth Comparison, By Region. 75

Chapter 6. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Region. 76
6.1. Global Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 76
       6.1.1. North America Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 76
                6.1.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 76
                6.1.1.2. Revenue (US$ Mn) Comparison, By End User. 77
                6.1.1.3. Revenue (US$ Mn) Comparison, By Test Type. 79
       6.1.2. Latin America Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 81
                6.1.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 81
                6.1.2.2. Revenue (US$ Mn) Comparison, By End User. 82
                6.1.2.3. Revenue (US$ Mn) Comparison, By Test Type. 84
       6.1.3. Europe Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 86
                6.1.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 86
                6.1.3.2. Revenue (US$ Mn) Comparison, By End User. 87
                6.1.3.3. Revenue (US$ Mn) Comparison, By Test Type. 89
       6.1.4. Japan Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 91
                6.1.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 91
                6.1.4.2. Revenue (US$ Mn) Comparison, By End User. 92
                6.1.4.3. Revenue (US$ Mn) Comparison, By Test Type. 94
       6.1.5. APEJ Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
                6.1.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 96
                6.1.5.2. Revenue (US$ Mn) Comparison, By End User. 97
                6.1.5.3. Revenue (US$ Mn) Comparison, By Test Type. 99
       6.1.6. MEA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
                6.1.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 101
                6.1.6.2. Revenue (US$ Mn) Comparison, By End User. 102
                6.1.6.3. Revenue (US$ Mn) Comparison, By Test Type. 104

Chapter 7. North America Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 106
7.1. US Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 106
       7.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 106
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 106
       7.1.3. Revenue (US$ Mn) Comparison, By Test Type. 107
7.2. Canada Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 108
       7.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 108
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 109
       7.2.3. Revenue (US$ Mn) Comparison, By Test Type. 110

Chapter 8. Latin America Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 111
8.1. Brazil Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 111
       8.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 111
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 111
       8.1.3. Revenue (US$ Mn) Comparison, By Test Type. 112
8.2. Mexico Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 113
       8.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 113
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 114
       8.2.3. Revenue (US$ Mn) Comparison, By Test Type. 115
8.3. Argentina Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 116
       8.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 116
       8.3.2. Revenue (US$ Mn) Comparison, By End User. 117
       8.3.3. Revenue (US$ Mn) Comparison, By Test Type. 118

Chapter 9. Europe Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 119
9.1. Germany Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 119
       9.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 119
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 119
       9.1.3. Revenue (US$ Mn) Comparison, By Test Type. 120
9.2. UK Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 121
       9.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 121
       9.2.2. Revenue (US$ Mn) Comparison, By End User. 122
       9.2.3. Revenue (US$ Mn) Comparison, By Test Type. 123
9.3. France Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 124
       9.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 124
       9.3.2. Revenue (US$ Mn) Comparison, By End User. 125
       9.3.3. Revenue (US$ Mn) Comparison, By Test Type. 126
9.4. Spain Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 127
       9.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 127
       9.4.2. Revenue (US$ Mn) Comparison, By End User. 127
       9.4.3. Revenue (US$ Mn) Comparison, By Test Type. 128
9.5. Italy Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 129
       9.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 129
       9.5.2. Revenue (US$ Mn) Comparison, By End User. 130
       9.5.3. Revenue (US$ Mn) Comparison, By Test Type. 131
9.6. Nordic Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 132
       9.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 132
       9.6.2. Revenue (US$ Mn) Comparison, By End User. 132
       9.6.3. Revenue (US$ Mn) Comparison, By Test Type. 133

Chapter 10. Japan Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 135
10.1. Japan Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 135
       10.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 135
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 135
       10.1.3. Revenue (US$ Mn) Comparison, By Test Type. 136

Chapter 11. APEJ Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 138
11.1. China Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 138
       11.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 138
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 138
       11.1.3. Revenue (US$ Mn) Comparison, By Test Type. 139
11.2. India Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 140
       11.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 140
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 141
       11.2.3. Revenue (US$ Mn) Comparison, By Test Type. 142
11.3. Malaysia Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 143
       11.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 143
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 143
       11.3.3. Revenue (US$ Mn) Comparison, By Test Type. 144
11.4. Thailand Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 145
       11.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 145
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 146
       11.4.3. Revenue (US$ Mn) Comparison, By Test Type. 147
11.5. Singapore Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 148
       11.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 148
       11.5.2. Revenue (US$ Mn) Comparison, By End User. 148
       11.5.3. . Revenue (US$ Mn) Comparison, By Test Type. 149
11.6. Australia Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 150
       11.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 150
       11.6.2. Revenue (US$ Mn) Comparison, By End User. 151
       11.6.3. Revenue (US$ Mn) Comparison, By Test Type. 152

Chapter 12. MEA Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 153
12.1. GCC Countries Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 153
       12.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 153
       12.1.2. .Revenue (US$ Mn) Comparison, By End User. 154
       12.1.3. Revenue (US$ Mn) Comparison, By Test Type. 155
12.2. South Africa Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 156
       12.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 156
       12.2.2. Revenue (US$ Mn) Comparison, By End User. 156
       12.2.3. . Revenue (US$ Mn) Comparison, By Test Type. 157
12.3. Nigeria Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 158
       12.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 158
       12.3.2. Revenue (US$ Mn) Comparison, By End User. 159
       12.3.3. Revenue (US$ Mn) Comparison, By Test Type. 160
12.4. Israel Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 161
       12.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 161
       12.4.2. Revenue (US$ Mn) Comparison, By End User. 161
       12.4.3. Revenue (US$ Mn) Comparison, By Test Type. 162

Chapter 13. Company Profiles. 164
13.1. Abbott Laboratories. 164
       13.1.1. Company Overview. 164
       13.1.2. Product Overview:. 164
       13.1.3. Key Financials:. 165
       13.1.4. SWOT Analysis. 165
       13.1.5. Key Developments. 165
13.2. Roche Holding AG.. 166
       13.2.1. Company Overview. 166
       13.2.2. Product Overview:. 166
       13.2.3. Key Financials:. 167
13.3. Thermo Fisher Scientific Inc.. 168
       13.3.1. Company Overview. 168
       13.3.2. Product Overview:. 168
       13.3.3. Key Financials:. 169
       13.3.4. SWOT Analysis. 169
       13.3.5. Key Developments. 169
13.4. Siemens AG. 170
       13.4.1. Company Overview. 170
       13.4.2. Product Overview:. 170
       13.4.3. Key Financials:. 171
       13.4.4. SWOT Analysis. 171
       13.4.5. Key Developments. 171
13.5. Bio-Rad Laboratories, Inc.. 172
       13.5.1. Company Overview. 172
       13.5.2. Product Overview:. 172
       13.5.3. SWOT Analysis. 173
       13.5.4. Key Developments. 175
13.6. Illumina, Inc.. 176
       13.6.1. Company Overview. 176
       13.6.2. Product Overview:. 176
       13.6.3. Key Financials:. 177
       13.6.4. SWOT Analysis. 177
       13.6.5. Key Development. 177
13.7. Epigenomics AG. 178
       13.7.1. Company Overview. 178
       13.7.2. Product Overview:. 178
       13.7.3. Key Financials. 179
       13.7.4. Key Developments. 179
       13.7.5. SWOT Analysis. 179
13.8. AstraZeneca plc. 184
       13.8.1. Company Overview. 184
       13.8.2. Product Overview:. 184
       13.8.3. Key Financials. 185
       13.8.4. Key Developments. 185
       13.8.5. SWOT Analysis. 185
13.9. Myriad Genetics Inc. 189
       13.9.1. Company Overview. 189
       13.9.2. Product Overview. 189
       13.9.3. Key Financials. 190
       13.9.4. SWOT Analysis. 190
13.10. Quest Diagnostics Incorporated. 194
       13.10.1. Company Overview. 194
       13.10.2. Product Overview. 194
       13.10.3. Key Financials. 195
       13.10.4. SWOT Analysis. 195

Chapter 14. Disclaimer and Contact information. 198

TABLE 1 Global Ovarian Cancer Diagnostics Market Value (US$ Mn), 2012-2016 22
TABLE 2 Global Ovarian Cancer Diagnostics Market Value (US$ Mn), 2017-2022 23
TABLE 3 Global Ovarian Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 24
TABLE 4 Global Epithelial Tumors Segment Value (US$ Mn), By Region 2012-2016 28
TABLE 5 Global Epithelial Tumors Segment Value (US$ Mn), By Region 2017-2022 29
TABLE 6 Global Epithelial Tumors Segment Market Share, By Region 2012-2016 30
TABLE 7 Global Epithelial Tumors Segment Market Share, By Region 2017-2022 30
TABLE 8 Global Epithelial Tumors Segment Y-o-Y, By Region 2015-2022 30
TABLE 9 Global Germ cell carcinoma tumors Segment Value (US$ Mn), By Region 2012-2016 31
TABLE 10 Global Germ cell carcinoma tumors Segment Value (US$ Mn), By Region 2017-2022 32
TABLE 11 Global Germ cell carcinoma tumors Segment Market Share, By Region 2012-2016 33
TABLE 12 Global Germ cell carcinoma tumors Segment Market Share, By Region 2017-2022 33
TABLE 13 Global Germ cell carcinoma tumors Segment Y-o-Y, By Region 2015-2022 33
TABLE 14 Global Stromal carcinoma tumors Segment Value (US$ Mn), By Region 2012-2016 34
TABLE 15 Global Stromal carcinoma tumors Segment Value (US$ Mn), By Region 2017-2022 35
TABLE 16 Global Stromal carcinoma tumors Segment Market Share, By Region 2012-2016 36
TABLE 17 Global Stromal carcinoma tumors Segment Market Share, By Region 2017-2022 36
TABLE 18 Global Stromal carcinoma tumors Segment Y-o-Y, By Region 2015-2022 36
TABLE 19 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2012-2016 38
TABLE 20 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2017-2022 39
TABLE 21 Global Hospital Associated Labs Segment Market Share, By Region 2012-2016 40
TABLE 22 Global Hospital Associated Labs Segment Market Share, By Region 2017-2022 40
TABLE 23 Global Hospital Associated Labs Segment Y-o-Y, By Region 2015-2022 40
TABLE 24 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2012-2016 41
TABLE 25 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2017-2022 42
TABLE 26 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2012-2016 43
TABLE 27 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2017-2022 43
TABLE 28 Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015-2022 43
TABLE 29 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2012-2016 44
TABLE 30 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2017-2022 45
TABLE 31 Global Cancer Research Institutes Segment Market Share, By Region 2012-2016 46
TABLE 32 Global Cancer Research Institutes Segment Market Share, By Region 2017-2022 46
TABLE 33 Global Cancer Research Institutes Segment Y-o-Y, By Region 2015-2022 46
TABLE 34 Global Others Segment Value (US$ Mn), By Region 2012-2016 47
TABLE 35 Global Others Segment Value (US$ Mn), By Region 2017-2022 48
TABLE 36 Global Others Segment Market Share, By Region 2012-2016 49
TABLE 37 Global Others Segment Market Share, By Region 2017-2022 49
TABLE 38 Global Others Segment Y-o-Y, By Region 2015-2022 49
TABLE 39 Global CA 125 Segment Value (US$ Mn), By Region 2012-2016 51
TABLE 40 Global CA 125 Segment Value (US$ Mn), By Region 2017-2022 51
TABLE 41 Global CA 125 Segment Market Share, By Region 2012-2016 52
TABLE 42 Global CA 125 Segment Market Share, By Region 2017-2022 53
TABLE 43 Global CA 125 Segment Y-o-Y, By Region 2015-2022 53
TABLE 44 Global HER 2 Segment Value (US$ Mn), By Region 2012-2016 54
TABLE 45 Global HER 2 Segment Value (US$ Mn), By Region 2017-2022 54
TABLE 46 Global HER 2 Segment Market Share, By Region 2012-2016 55
TABLE 47 Global HER 2 Segment Market Share, By Region 2017-2022 56
TABLE 48 Global HER 2 Segment Y-o-Y, By Region 2015-2022 56
TABLE 49 Global BRCA Segment Value (US$ Mn), By Region 2012-2016 57
TABLE 50 Global BRCA Segment Value (US$ Mn), By Region 2017-2022 57
TABLE 51 Global BRCA Segment Market Share, By Region 2012-2016 58
TABLE 52 Global BRCA Segment Market Share, By Region 2017-2022 59
TABLE 53 Global BRCA Segment Y-o-Y, By Region 2015-2022 59
TABLE 54 Global CEA Segment Value (US$ Mn), By Region 2012-2016 60
TABLE 55 Global CEA Segment Value (US$ Mn), By Region 2017-2022 60
TABLE 56 Global CEA Segment Market Share, By Region 2012-2016 61
TABLE 57 Global CEA Segment Market Share, By Region 2017-2022 62
TABLE 58 Global CEA Segment Y-o-Y, By Region 2015-2022 62
TABLE 59 Global ER & PR segment Value (US$ Mn), By Region 2012-2016 63
TABLE 60 Global ER & PR segment Value (US$ Mn), By Region 2017-2022 63
TABLE 61 Global ER & PR segment Market Share, By Region 2012-2016 64
TABLE 62 Global ER & PR segment Market Share, By Region 2017-2022 65
TABLE 63 Global ER & PR segment Y-o-Y, By Region 2015-2022 65
TABLE 64 Global KRAS Mutation Segment Value (US$ Mn), By Region 2012-2016 66
TABLE 65 Global KRAS Mutation Segment Value (US$ Mn), By Region 2017-2022 66
TABLE 66 Global KRAS Mutation Segment Market Share, By Region 2012-2016 67
TABLE 67 Global KRAS Mutation Segment Market Share, By Region 2017-2022 68
TABLE 68 Global KRAS Mutation Segment Y-o-Y, By Region 2015-2022 68
TABLE 69 Global Others Segment Value (US$ Mn), By Region 2012-2016 69
TABLE 70 Global Others Segment Value (US$ Mn), By Region 2017-2022 69
TABLE 71 Global Others Segment Market Share, By Region 2012-2016 70
TABLE 72 Global Others Segment Market Share, By Region 2017-2022 71
TABLE 73 Global Others Segment Y-o-Y, By Region 2015-2022 71
TABLE 74 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 72
TABLE 75 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 72
TABLE 76 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 73
TABLE 77 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 74
TABLE 78 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 75
TABLE 79 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 76
TABLE 80 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 77
TABLE 81 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 77
TABLE 82 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 78
TABLE 83 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 79
TABLE 84 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 80
TABLE 85 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 81
TABLE 86 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 82
TABLE 87 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 82
TABLE 88 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 83
TABLE 89 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 84
TABLE 90 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 85
TABLE 91 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 86
TABLE 92 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 87
TABLE 93 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 87
TABLE 94 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 88
TABLE 95 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 89
TABLE 96 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 90
TABLE 97 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 91
TABLE 98 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 92
TABLE 99 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 92
TABLE 100 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 93
TABLE 101 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 94
TABLE 102 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 95
TABLE 103 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 96
TABLE 104 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 97
TABLE 105 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 97
TABLE 106 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 98
TABLE 107 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 99
TABLE 108 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 100
TABLE 109 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 101
TABLE 110 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 102
TABLE 111 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 102
TABLE 112 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 102
TABLE 113 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 103
TABLE 114 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 103
TABLE 115 US Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 104
TABLE 116 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 104
TABLE 117 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 105
TABLE 118 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 105
TABLE 119 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 105
TABLE 120 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 106
TABLE 121 Canada Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 106
TABLE 122 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 107
TABLE 123 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 107
TABLE 124 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 107
TABLE 125 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 108
TABLE 126 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 108
TABLE 127 Brazil Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 109
TABLE 128 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 109
TABLE 129 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 110
TABLE 130 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 110
TABLE 131 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 110
TABLE 132 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 111
TABLE 133 Mexico Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 111
TABLE 134 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 112
TABLE 135 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 112
TABLE 136 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 113
TABLE 137 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 113
TABLE 138 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 114
TABLE 139 Argentina Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 114
TABLE 140 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 115
TABLE 141 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 115
TABLE 142 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 115
TABLE 143 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 116
TABLE 144 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 116
TABLE 145 Germany Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 117
TABLE 146 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 117
TABLE 147 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 118
TABLE 148 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 118
TABLE 149 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 118
TABLE 150 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 119
TABLE 151 UK Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 119
TABLE 152 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 120
TABLE 153 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 120
TABLE 154 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 121
TABLE 155 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 121
TABLE 156 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 122
TABLE 157 France Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 122
TABLE 158 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 123
TABLE 159 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 123
TABLE 160 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 123
TABLE 161 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 124
TABLE 162 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 124
TABLE 163 Spain Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 125
TABLE 164 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 125
TABLE 165 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 125
TABLE 166 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 126
TABLE 167 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 126
TABLE 168 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 127
TABLE 169 Italy Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 127
TABLE 170 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 128
TABLE 171 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 128
TABLE 172 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 128
TABLE 173 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 129
TABLE 174 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 129
TABLE 175 Nordic Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 130
TABLE 176 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 131
TABLE 177 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 131
TABLE 178 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 131
TABLE 179 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 132
TABLE 180 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 132
TABLE 181 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 133
TABLE 182 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 134
TABLE 183 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 134
TABLE 184 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 134
TABLE 185 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 135
TABLE 186 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 135
TABLE 187 China Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 136
TABLE 188 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 136
TABLE 189 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 136
TABLE 190 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 137
TABLE 191 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 137
TABLE 192 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 138
TABLE 193 India Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 138
TABLE 194 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 139
TABLE 195 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 139
TABLE 196 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 139
TABLE 197 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 140
TABLE 198 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 140
TABLE 199 Malaysia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 141
TABLE 200 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 141
TABLE 201 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 141
TABLE 202 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 142
TABLE 203 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 142
TABLE 204 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 143
TABLE 205 Thailand Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 143
TABLE 206 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 144
TABLE 207 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 144
TABLE 208 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 144
TABLE 209 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 145
TABLE 210 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 145
TABLE 211 Singapore Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 146
TABLE 212 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 146
TABLE 213 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 146
TABLE 214 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 147
TABLE 215 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 147
TABLE 216 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 148
TABLE 217 Australia Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 148
TABLE 218 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 149
TABLE 219 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 149
TABLE 220 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 150
TABLE 221 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 150
TABLE 222 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 151
TABLE 223 GCC Countries Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 151
TABLE 224 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 152
TABLE 225 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 152
TABLE 226 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 152
TABLE 227 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 153
TABLE 228 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 153
TABLE 229 South Africa Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 154
TABLE 230 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 154
TABLE 231 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 154
TABLE 232 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 155
TABLE 233 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 155
TABLE 234 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 156
TABLE 235 Nigeria Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 156
TABLE 236 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 157
TABLE 237 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 157
TABLE 238 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 157
TABLE 239 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 158
TABLE 240 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 158
TABLE 241 Israel Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 159

 

FIG. 1 Global Ovarian Cancer Diagnostics Market Value (US$ Mn), 2012-2016 11
FIG. 2 Global Ovarian Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2022 11
FIG. 3 Global Ovarian Cancer Diagnostics Market Value (US$ Mn) and Y-o-Y, 2015-2022 13
FIG. 4 Global Epithelial Tumors Segment Market Value (US$ Mn) By Region, 2012-2016 16
FIG. 5 Global Epithelial Tumors Segment Market Value (US$ Mn) By Region, 2017-2022 17
FIG. 6 Global Epithelial Tumors Segment Y-o-Y Growth Rate, By Region, 2015-2022 19
FIG. 7 Global Germ cell carcinoma tumors Segment Market Value (US$ Mn) By Region, 2012-2016 19
FIG. 8 Global Germ cell carcinoma tumors Segment Market Value (US$ Mn) By Region, 2017-2022 20
FIG. 9 Global Germ cell carcinoma tumors Segment Y-o-Y Growth Rate, By Region, 2015-2022 22
FIG. 10 Global Stromal carcinoma tumors Segment Market Value (US$ Mn) By Region, 2012-2016 22
FIG. 11 Global Stromal carcinoma tumors Segment Market Value (US$ Mn) By Region, 2017-2022 23
FIG. 12 Global Stromal carcinoma tumors Segment Y-o-Y Growth Rate, By Region, 2015-2022 25
FIG. 13 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2012-2016 26
FIG. 14 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017-2022 27
FIG. 15 Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2015-2022 29
FIG. 16 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2012-2016 29
FIG. 17 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017-2022 30
FIG. 18 Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2015-2022 32
FIG. 19 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2012-2016 32
FIG. 20 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017-2022 33
FIG. 21 Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2015-2022 35
FIG. 22 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 35
FIG. 23 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 36
FIG. 24 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 38
FIG. 25 Global CA 125 Segment Market Value (US$ Mn) By Region, 2012-2016 39
FIG. 26 Global CA 125 Segment Market Value (US$ Mn) By Region, 2017-2022 40
FIG. 27 Global CA 125 Segment Y-o-Y Growth Rate, By Region, 2015-2022 41
FIG. 28 Global HER 2 Segment Market Value (US$ Mn) By Region, 2012-2016 42
FIG. 29 Global HER 2 Segment Market Value (US$ Mn) By Region, 2017-2022 43
FIG. 30 Global HER 2 Segment Y-o-Y Growth Rate, By Region, 2015-2022 44
FIG. 31 Global BRCA Segment Market Value (US$ Mn) By Region, 2012-2016 45
FIG. 32 Global BRCA Segment Market Value (US$ Mn) By Region, 2017-2022 46
FIG. 33 Global BRCA Segment Y-o-Y Growth Rate, By Region, 2015-2022 47
FIG. 34 Global CEA Segment Market Value (US$ Mn) By Region, 2012-2016 48
FIG. 35 Global CEA Segment Market Value (US$ Mn) By Region, 2017-2022 49
FIG. 36 Global CEA Segment Y-o-Y Growth Rate, By Region, 2015-2022 50
FIG. 37 Global ER & PR segment Market Value (US$ Mn) By Region, 2012-2016 51
FIG. 38 Global ER & PR segment Market Value (US$ Mn) By Region, 2017-2022 52
FIG. 39 Global ER & PR segment Y-o-Y Growth Rate, By Region, 2015-2022 53
FIG. 40 Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2012-2016 54
FIG. 41 Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2017-2022 55
FIG. 42 Global KRAS Mutation Segment Y-o-Y Growth Rate, By Region, 2015-2022 56
FIG. 43 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016 57
FIG. 44 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022 58
FIG. 45 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022 59
FIG. 46 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 60
FIG. 47 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 61
FIG. 48 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 62
FIG. 49 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 62
FIG. 50 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 63
FIG. 51 North America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 64
FIG. 52 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 65
FIG. 53 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 66
FIG. 54 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 67
FIG. 55 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 67
FIG. 56 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 68
FIG. 57 Latin America Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 69
FIG. 58 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 70
FIG. 59 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 71
FIG. 60 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 72
FIG. 61 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 72
FIG. 62 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 73
FIG. 63 Europe Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 74
FIG. 64 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 75
FIG. 65 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 76
FIG. 66 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 77
FIG. 67 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 77
FIG. 68 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 78
FIG. 69 Japan Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 79
FIG. 70 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 80
FIG. 71 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 81
FIG. 72 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 82
FIG. 73 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 82
FIG. 74 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 83
FIG. 75 APEJ Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 84
FIG. 76 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2012-2016 85
FIG. 77 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Cancer Type 2017-2022 86
FIG. 78 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2012-2016 87
FIG. 79 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By End User 2017-2022 87
FIG. 80 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2012-2016 88
FIG. 81 MEA Ovarian Cancer Diagnostics Market Value (US$ Mn), By Test Type 2017-2022 89

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development